Tirzepatide Research Hub (GIP+GLP-1 Dual Agonist) | Mechanism, SURPASS & SURMOUNT Data
Tirzepatide is the first approved dual incretin receptor agonist — simultaneously activating GLP-1R and GIPR to produce metabolic effects that exceed selective GLP-1R agonism in every head-to-head trial. This hub covers the dual mechanism in depth, the full SURPASS and SURMOUNT clinical dataset, cardiovascular outcomes status, and research protocols for dual vs single receptor comparison studies.
Dual GIP+GLP-1R
Mechanism — unique among approved drugs
22.5%
SURMOUNT-1 weight reduction (15mg, 72 wk)
SURMOUNT-5
Head-to-head vs semaglutide: tirzepatide wins
≥99%
QSC purity — HPLC + MS
Mechanism: Why Two Receptors Beat One
Semaglutide activates only GLP-1R. Tirzepatide was engineered as a single synthetic peptide (39 amino acids) with dual GLP-1R and GIPR agonist activity — not a mixture, but one molecule designed for balanced co-agonism at both incretin receptors. The rationale: GLP-1R and GIPR are complementary receptors that evolved to mediate the incretin effect of nutrient ingestion. Activating both simultaneously produces additive or synergistic metabolic effects that neither receptor can achieve alone.
GLP-1R contribution in tirzepatide
GLP-1R activation provides: glucose-dependent insulin secretion from pancreatic beta cells; glucagon suppression from alpha cells; gastric emptying delay reducing postprandial glucose excursions; and hypothalamic appetite suppression via POMC/CART stimulation and NPY/AgRP inhibition. These are the well-characterised effects from the semaglutide and liraglutide literature — tirzepatide preserves them in full.
GIPR contribution — the tirzepatide differentiator
GIPR adds multiple mechanisms absent from selective GLP-1R agonists: amplified insulin secretion (particularly at lower glucose concentrations where GLP-1R effect is minimal); direct adipose lipolysis and thermogenesis via GIPR in adipose tissue; adiponectin secretion from adipocytes; and — critically — appears to sensitise or potentiate GLP-1R signalling in hypothalamic appetite circuits, producing a supra-additive appetite-suppressing effect. The adipose GIPR activation may also independently promote fat oxidation and energy expenditure beyond what GLP-1R mediated appetite suppression achieves through reduced intake alone.
The GIPR paradox: why agonism beats antagonism
Early research suggested GIPR antagonism might improve metabolic outcomes (GIP was considered ‘the other incretin’ with unclear benefit). Tirzepatide’s clinical success with GIPR agonism resolved this — GIPR agonism, not antagonism, provides the metabolic benefit. The proposed explanation is that GIPR in adipose tissue and the hypothalamus has beneficial effects that are separate from its pancreatic insulin-secreting role. Tirzepatide’s clinical data made the GIPR agonism vs antagonism debate one of the most consequential resolved questions in incretin pharmacology.
SURPASS Program: Type 2 Diabetes Phase 3 Data
The SURPASS program comprised six Phase 3 trials across T2D populations, establishing tirzepatide as the most effective approved pharmacotherapy for HbA1c reduction in T2D:
Trial
Comparator
n
Duration
HbA1c reduction (15mg)
Weight reduction (15mg)
SURPASS-1 (2021)
Placebo
478
40 wk
−2.07%
−9.5kg
SURPASS-2 (2021)
Semaglutide 1mg
1,879
40 wk
−2.30% vs −1.86%
−11.2kg vs −5.7kg
SURPASS-3 (2021)
Insulin degludec
1,444
52 wk
−2.37% vs −1.34%
−12.9kg vs +2.3kg
SURPASS-4 (2021)
Insulin glargine
2,002
104 wk
−2.58% vs −1.44%
−13.0kg vs +1.6kg
SURPASS-5 (2021)
+ Insulin glargine
475
40 wk
−2.11%
−9.5kg
SURPASS-CVOT (2024)
Dulaglutide 1.5mg
5,620
~3 yr
Superior
−11.2kg vs −1.0kg
SURMOUNT Program: Obesity Phase 3 Data
Trial
Population
n
Duration
Mean weight reduction
Key finding
SURMOUNT-1 (2022)
Obese, non-T2D
2,539
72 wk
−15.0 / −19.5 / −20.9% (5/10/15mg)
37% achieved ≥25% weight reduction at 15mg
SURMOUNT-2 (2023)
Obese + T2D
938
72 wk
−13.4 / −15.7% (10/15mg)
First obesity approval data in T2D population
SURMOUNT-3 (2023)
Obese, lifestyle lead-in
579
72 wk
−26.6% (15mg)
Lead-in lifestyle intervention enhanced weight loss
SURMOUNT-4 (2023)
Obese, maintenance
670
88 wk
Regain 14% on withdrawal
Confirms sustained treatment required for maintenance
SURMOUNT-5 (2025)
Obese, vs sema 2.4mg
751
72 wk
~−20.2% vs ~−13.7%
First prospective head-to-head — tirzepatide statistically superior
SURMOUNT-MMO
Obese + established CVD
pending
~4 yr
Pending
Cardiovascular superiority vs placebo (ongoing)
SURPASS-2 and SURMOUNT-5: The Head-to-Head Evidence
Two trials directly compare tirzepatide to semaglutide, at different dose contexts and patient populations:
SURPASS-2 compared tirzepatide (5/10/15mg) vs semaglutide 1mg in T2D over 40 weeks. All three tirzepatide doses achieved superior HbA1c reduction; tirzepatide 10mg and 15mg achieved superior weight reduction. This established that dual GIP+GLP-1R agonism outperforms selective GLP-1R agonism in the standard T2D dosing context.
SURMOUNT-5 (2025) was the first prospective head-to-head obesity trial, comparing tirzepatide 15mg vs semaglutide 2.4mg (both at their maximum approved obesity doses) in obese patients without diabetes. Tirzepatide produced approximately 20.2% mean weight reduction vs 13.7% for semaglutide at 72 weeks — a ~6–7 percentage point absolute difference. This is the definitive comparative dataset for researchers designing tirzepatide vs semaglutide studies.
NASH and Liver Research
Tirzepatide is one of the most studied compounds in NASH (non-alcoholic steatohepatitis) / MASH (metabolic dysfunction-associated steatohepatitis) research. The SYNERGY-NASH trial (2024) demonstrated tirzepatide produced NASH resolution without worsening fibrosis in 62.4% of participants at the 10mg dose — among the strongest results for any single agent in NASH. The proposed mechanisms include hepatic lipid reduction via GLP-1R and GIPR-mediated lipolysis, reduction in hepatic inflammation via systemic adipokine improvement, and direct hepatic GLP-1R and GIPR signalling effects on hepatocyte fat metabolism and inflammation.
Cardiovascular Research Status
SURPASS-CVOT (2024) established tirzepatide non-inferior to dulaglutide (an approved GLP-1R agonist with known cardiovascular benefit) for MACE — meaning tirzepatide carries at minimum the cardiovascular safety profile of the GLP-1R agonist class. SURMOUNT-MMO, the dedicated cardiovascular superiority trial in obese non-T2D patients with established CVD, is ongoing. Its results will determine whether tirzepatide achieves MACE superiority analogous to semaglutide’s 20% MACE reduction in SELECT (2023). The research community considers SURMOUNT-MMO the most consequential pending cardiovascular outcomes result in metabolic medicine.
Research Protocols
Model
Dose range
Route
Duration
Key endpoints
DIO rodent — weight reduction
0.01–1mg/kg weekly
SC injection
8–16 wk
Body weight, fat mass, food intake, metabolic cage energy expenditure
GSIS amplitude vs semaglutide, intracellular Ca2+, cAMP, GLP-1R+GIPR co-stimulation kinetics
QSC Tirzepatide: Quality Specifications
QSC tirzepatide is a 39-amino acid synthetic peptide synthesised in-house via Fmoc SPPS at our Qingdao facility. As a longer dual-modified peptide, MS verification of correct molecular weight is particularly critical — confirming full-length intact peptide rather than truncated synthesis products. Every batch is HPLC verified at ≥99% purity with Janoshik-independent COA published on the product page.
Specification
QSC Standard
Purity
≥99% by HPLC peak area
Identity
MS molecular weight confirmed — every batch
COA
Janoshik-independent, publicly verifiable
Manufacture
In-house Fmoc SPPS — Qingdao facility
Reconstitution
Bacteriostatic water — 1mg/mL stock; refrigerate; use within 3–4 weeks
Domestic shipping
USA, EU, UK, Canada, Australia — 5-region domestic network
Frequently Asked Questions
What is tirzepatide?
Tirzepatide (brand names Mounjaro for T2D, Zepbound for obesity) is a once-weekly injectable synthetic peptide that simultaneously co-activates two incretin receptors: GLP-1R (glucagon-like peptide-1 receptor) and GIPR (glucose-dependent insulinotropic polypeptide receptor). This dual mechanism — unique among approved drugs — produces greater HbA1c reduction and weight reduction than selective GLP-1R agonists in Phase 3 head-to-head trials. It is FDA approved for type 2 diabetes (2022) and obesity (2023).
How does tirzepatide compare to semaglutide?
SURPASS-2 directly compared tirzepatide (5, 10, 15mg) vs semaglutide 1mg in T2D — all three tirzepatide doses produced greater HbA1c reduction; 10mg and 15mg produced greater weight reduction. SURMOUNT-5 (2025) was the first head-to-head obesity trial: tirzepatide 15mg vs semaglutide 2.4mg, showing ~20.2% vs ~13.7% mean weight reduction at 72 weeks. Tirzepatide’s advantage is attributed to additive GIPR co-agonism on top of GLP-1R activation.
What is the GIPR and why does it matter?
GIPR (glucose-dependent insulinotropic polypeptide receptor) is a class B GPCR, closely related to GLP-1R. GIPR is highly expressed in pancreatic beta cells, adipose tissue, bone, and brain. In adipose tissue, GIPR activation promotes lipolysis, thermogenesis, and — paradoxically — may sensitise GLP-1R signalling in hypothalamic appetite circuits. The addition of GIPR co-agonism to GLP-1R agonism is the mechanistic explanation for tirzepatide’s greater weight reduction vs selective GLP-1R agonists.
What are the SURPASS and SURMOUNT trial programs?
SURPASS is tirzepatide’s Phase 3 T2D program (SURPASS-1 through SURPASS-6), demonstrating HbA1c reductions of 1.87–2.58% and weight reductions of 7–15kg across doses. SURMOUNT is the obesity program (SURMOUNT-1 through SURMOUNT-5): SURMOUNT-1 showed up to 22.5% weight reduction at 72 weeks (15mg, non-T2D). SURMOUNT-5 (2025) was the first head-to-head with semaglutide 2.4mg, confirming tirzepatide’s superiority.
Does tirzepatide have cardiovascular benefits?
Yes. SURPASS-CVOT (2024) demonstrated tirzepatide non-inferior to dulaglutide for MACE in high-risk T2D patients. SURMOUNT-MMO, the dedicated cardiovascular superiority trial in obese non-T2D patients, is ongoing — its results will determine whether tirzepatide achieves the same MACE superiority as semaglutide’s SELECT trial (20% reduction). Early biomarker and blood pressure data from SURPASS trials is consistently favourable.
What is tirzepatide used for in laboratory research?
Research applications include: dual GIP+GLP-1 receptor co-agonism pharmacology; comparison with semaglutide to isolate the GIPR contribution by subtraction; comparison with retatrutide to study the added value of GCGR co-agonism; T2D and DIO rodent metabolic models; adipose GIP receptor biology; NASH/MASH liver fibrosis models; cardiovascular mechanistic research; and beta cell function studies.
Research Use Only: All products sold on qsc-usa.com are intended strictly for laboratory research purposes only. They are not approved for human consumption, veterinary use, or any other application.
